{"entity":{"id":"idea-bio1-adaptive-car-antigen-switch","kind":"idea","name":"Plan the second CAR-T target before the first one is lost","aka":[],"tldr":"Cell therapies fail when the tumour stops showing the marker they were built to find. Preparing an alternative product in advance would let doctors switch quickly.","summary":"Antigen-negative relapse accounts for a substantial share of CAR-T failures in B-cell malignancies and is emerging in multiple myeloma. Strategies include dual-target and tandem CARs, sequential products, and adaptor or universal CAR platforms whose specificity is set by a separately dosed molecule. A pragmatic programme would monitor antigen density after infusion and have the alternative product manufactured or an adaptor available before relapse.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)","url":"https://doi.org/10.1056/NEJMoa1713137"}],"tags":[],"related":[],"cancers":["dlbcl","multiple-myeloma","all-leukemia"],"sections":[],"technologies":["car-t","allogeneic-cell-therapy","mrd-testing"],"targets":["cd19","cd20","bcma","gprc5d"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mrd"],"trials":[],"people":[],"bottlenecks":["b-resistance","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Pre-planned antigen switching, triggered by falling antigen density or early molecular relapse rather than by overt relapse, improves durable remission rates compared with reactive switching at relapse.","rationale":"Antigen loss is detectable before clinical relapse using flow cytometry and MRD assays; the delay in manufacturing a second product is usually what makes switching too late.","test":"Single-arm study of antigen-density and MRD-triggered pre-emptive switching in relapsed B-cell malignancy, with durable remission at two years compared with historical reactive management.","maturity":"early-clinical","actor":"clinic","cost":"medium","horizonYears":5},"route":"/ideas/idea-bio1-adaptive-car-antigen-switch/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}]}}